- Home
- GWRS vs RCEL Comparison
GWRS vs RCEL Comparison
Compare GWRS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- RCEL
- Stock Information
- Founded
- GWRS 2003
- RCEL N/A
- Country
- GWRS United States
- RCEL United States
- Employees
- GWRS N/A
- RCEL N/A
- Industry
- GWRS Water Supply
- RCEL Medical/Dental Instruments
- Sector
- GWRS Utilities
- RCEL Health Care
- Exchange
- GWRS Nasdaq
- RCEL Nasdaq
- Market Cap
- GWRS 286.0M
- RCEL 161.5M
- IPO Year
- GWRS 2010
- RCEL N/A
- Fundamental
- Price
- GWRS $10.21
- RCEL $5.42
- Analyst Decision
- GWRS
- RCEL Strong Buy
- Analyst Count
- GWRS 0
- RCEL 4
- Target Price
- GWRS N/A
- RCEL $16.50
- AVG Volume (30 Days)
- GWRS 51.1K
- RCEL 316.4K
- Earning Date
- GWRS 08-06-2025
- RCEL 08-07-2025
- Dividend Yield
- GWRS 2.99%
- RCEL N/A
- EPS Growth
- GWRS N/A
- RCEL N/A
- EPS
- GWRS 0.23
- RCEL N/A
- Revenue
- GWRS $53,539,000.00
- RCEL $71,661,000.00
- Revenue This Year
- GWRS $8.31
- RCEL $57.16
- Revenue Next Year
- GWRS $6.52
- RCEL $36.69
- P/E Ratio
- GWRS $44.21
- RCEL N/A
- Revenue Growth
- GWRS 3.94
- RCEL 41.35
- 52 Week Low
- GWRS $9.37
- RCEL $4.71
- 52 Week High
- GWRS $13.98
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- GWRS 45.02
- RCEL 43.61
- Support Level
- GWRS $10.05
- RCEL $5.11
- Resistance Level
- GWRS $10.59
- RCEL $5.55
- Average True Range (ATR)
- GWRS 0.27
- RCEL 0.31
- MACD
- GWRS -0.03
- RCEL 0.10
- Stochastic Oscillator
- GWRS 15.54
- RCEL 69.61
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.